NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S.



Similar documents
AMYVID FORBETAPIR (F 18) Q.S. ELI LILLY NEDERLAND BV New AS ARZERRA OFATUMUMAB MG/ML GLAXO GROUP LTD Conditional auth, PASS

NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S.

NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S.

NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S.

NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S.

13 ADDITIONS - 1 RETRAIT

comparison of access and reimbursement environments A report benchmarking Australia s access to new medicines Edition 1

NEW DRUG APPROVALS IN ICH COUNTRIES FOCUS ON 2013

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use

Specialty Pipeline Update

PATIENT ASSISTANCE PROGRAMS

ATC/DDD Classification

Manufacturer of drug substance

Biggest Launches 2014

Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct

Special Authorization

WORLD PREVIEW 2014, OUTLOOK TO 2020

Lists of medicinal products for rare diseases in Europe*

The Newcastle upon Tyne Hospitals NHS Foundation Trust. Handling, Segregation and Disposal of Cytostatic and Cytotoxic Waste

Drugs Not Approved By the Scottish Medicines Consortium

Clinical trial research agreement Agreed schedule 4 or 7 clause amendments

Monitoring Usage in Wales of Medicines Appraised by NICE and AWMSG

Liste des médicaments pour les maladies rares en Europe*

Annual Press Conference Business Year 2011

EU Clinical Trials Register

Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus)

List of nationally authorised medicinal products

1 ST QUARTER 2015 UPDATE CHANGES TO THE HIGHMARK DRUG FORMULARIES

CHEM-E4140 Selectivity 12. Pharma Business

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality

Pharma working capital performance highly variable

Guide. Astellas Pharma US, Inc. XTANDI Access Services SM 2015 NCCN Virtual Reimbursement Resource Room. NCCN.org/reimbursement

Metastatic Breast Cancer - Pipeline Review, Q1 2011

KEEPING CLINICAL TRIALS IN AUSTRALIA

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use

The power of creativity Pharmaceutical Branding 2012

Medical School for Actuaries. June 12, Baltimore, Maryland

ehealthinsight Series: Online Patient Recruitment Strategies

Elenchi dei prodotti medicinali per le malattie rare in Europa*

Listados de medicamentos para enfermedades raras en Europa*

Stakeholder Perspectives: Mild Cognitive Impairment and Dementia

Multiple Sclerosis Therapeutics to Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

Human Tubal Fluid (HTF) Media & Modifi ed Human Tubal Fluid (mhtf) Medium with Gentamicin

Pharma working capital leaves room for improvement

FDA Office of Hematology and Oncology Products (OHOP) 2011 Review

Global Non-Small Cell Lung Cancer Therapeutics Market

Commercial Insight Osteoarthritis and Rheumatoid Arthritis

Verzeichnis der Arzneimittel für seltene Krankheiten in Europa*

EvaluatePharma World Preview 2015, Outlook to 2020

Rx-360 An International Pharmaceutical Supply Chain Consortium

Malignant Mesothelioma - Pipeline Review, H1 2015

Listes des médicaments pour les maladies rares en Europe*

Preferred Drug List Updates Effective: Jan. 1, 2016

Review of the List of High-Cost Medicines used by the Dominican Republic s Protected Diseases Program and Planning of Purchases for 2015

Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants

The type 2 diabetes market is undergoing a paradigm

BOLT Hem/Onc Thought Leader Panel #38 Cancer Immunotherapy

SMC Accepted Medicine Indication Formulary Decision To be used on Treatment of unresectable or metastatic, well- or everolimus (Afinitor) Novartis

Pharmaceutical Marketing Disclosures

Pain management for cancer patients Acute Ischemic Stroke. Hemophilia, Von willebrand disease & Bleeding disorders. Infectious Disease

Marketing authorisations granted in March 2016

Orphan drugs program. Discussion paper. May 2015

Stakeholder Insight: Insulin Use in Type 2 Diabetes

May 2013 Declining Medicine Use and Costs: For Better or Worse?

Great-West s Drug Prior Authorization

Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013

REFERENCE CODE GDHC96PIDR PUBLICATION DATE APRIL 2015 PROSTATE CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023

Fourth Quarter 2014 Provider Connection

Drug Formulary Update, July 2014 Commercial and State Programs

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013

Indication: Posology: Indication: Posology:

Global Pharmaceuticals Marketing Channel Reference EDITION

Robert Ancuceanu for his exceptional work as he has resigned from the Committee and adopted the following opinions:

supplement 18 PAYS D'ORIGINE NOM DOSAGE FORME NR ST LABORATOIRE 4ML CONCENTRATE FOR SOLUTION FOR INFUSION x 1VIAL

meeting report on the review of applications for orphan designation

Commercial Perspectives: Multiple Sclerosis

CODE FOR DISCLOSURE OF TRANSFERS OF VALUE BY PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTH ORGANIZATIONS

Juli 2016 Verzeichnis der Arzneimittel für seltene Krankheiten in Europa*

M&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends

Global Peptide Therapeutics Market

PAYS D'ORIGINE NOM DOSAGE FORME NR ST LABORATOIRE A-CNOTREN 20MG 30 SOFT CAPSULES /09 * GAP S.A FOR PHARMATHEN S.A GRECE ACUVAIL 0.

Novel OAC s : How should we use them?

Malignant Pleural Mesothelioma - Pipeline Review, H2 2014

Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C. Daclatasvir (Daklinza, DCV, BMS )

SPECIAL AUTHORIZATION GUIDELINES

GSK Product development pipeline

drugs in development CuraScript Specialty Pharmacy Management Guide & Trend Report

Multiple Sclerosis Drug Discoveries - What the Future Holds

Listes des médicaments pour les maladies rares en Europe*

Biopharmaceutical Raw Materials throughout the Product Lifecycle

New Drug Approvals. Elizabeth A. Shlom, PharmD, BCPS President, NYSCHP SVP/Director, Clinical Pharmacy Services GNYHA Services, Inc.

DRUGS BILLED UNDER MISCELLANEOUS CODES J3490, J3590, J9999 OR C9399 COVERAGE INFORMATION

Stakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm

Transcription:

Final Belgian list: (Last update 13/03/2015) marketing name Active substance MAH Reason on list ABASRIA INSULINE GLARGINE ELI LILLY REGIONAL OPERATIONS GMBH New Biological ACCOFIL FILGASTRIM ACCORD HEALTHCARE LIMITED New Biological ADCETRIS BRENTUXIMAB VEDOTINE TAKEDA GLOBAL R&D CENTRE (EUROPE) LTD, Cond Auth, ADEMPAS RIOCIGUAT BAYER PHARMA ALDURAZYME LARONIDASE GENZYME EUROPE B.V. Auth under excep circumstances, AMYVID FORBETAPIR (F-18) Q.S. ELI LILLY NEDERLAND BV ANORO GLAXO GROUP LTD UMECLIDINIUM BROMIDE, VILANTEROL TRIFENATATE, APLEEK ETHINYL ESTRADIOL/GESTODENE BAYER PHARMA AG ARZERRA OFATUMUMAB 20.00 MG/ML GLAXO GROUP LTD Conditional auth, ATRIANCE NELARABINE 5.00 MG/ML GLAXO GROUP LTD Auth under excep circumstances ATRYN ANTITHROMBIN ALFA GTC BIOTHERAPEUTICS UK LIMITED Auth under excep circumstances, AUBAGIO TERIFLUNOMIDE SANOFI-AVENTIS GROUPE BELLINA CHLORMADINONE, ETHINYLESTRADIOL GEDEON RICHTER Plc Outcome Referral Art 31, BEMFOLA Follitropin alfa FINOX Biotech AG New biological BENLYSTA BELIMUMAB GLAXO GROUP LTD BETMIGA MIRABEGRON ASTELLAS PHARMA EUROPE B.V. BEXSERO NEISSERIA MENINGITIDES B, RECOMBINANT, COMPONENT, ADSORBED Q.S. NOVARTIS VACCINES & DIAGNOSTICS S.R.L. BINDREN COLESTILAN NOVARTIS VACCINES & DIAGNOSTICS S.R.L. BOSULIF BOSUTINIB (MONOHYDRATE) 100.00 MG PFIZER LIMITED, Cond Auth, BRETARIS GENUAIR ACLIDINIUM BROMIDE ALMIRALL S.A, BRIMICA GENUAIR ACLIDINIUM BROMIDE/ FORMOTERL FUMARATE DIHYDRATE ALMIRALL S.A, BRINTELLIX VORTIOXETINE H. LUNDBECK A/S CAPRELSA VANDETANIB ASTRAZENECA AB, Cond Auth CEPLENE HISTAMINE DIHYDROCHLORIDE MEDA AB Auth under excep circumstances CERDELGA ELIGLUSTAT GENZYME EUROPE B.V., CHAMPIX VARENICLINE (TARTRATE) PFIZER LIMITED CINRYZE C1-INHIBITOR 500.00 IU VIROPHARMA BVBA CLAUDIA - 35 ETHINYLESTRADIOL 35.00 MCG, CYPROTERONE ACETATE 2.00 MG SANDOZ N.V. CLEVIPREX CLEVIDIPINE BUTYRATE THE MEDICINES COMPANY UK LTD COMETRIQ CABOZANTINIB TMC Pharma Services Ltd, Cond Auth CONSTELLA LINACLOTIDE ALMIRALL S.A CONVULEX VALPROIC ACID TAKEDA BELGIUM CORLENTOR IVABRADINE SERVIER, LES LABORATOIRES

COSENTYX SECUKINUMAB NOVARTIS EUROPHARM LIMITED CUPRYMINA COPPER (64-CU) CHLORIDE Q.S. SPARKLE S.R.L CYRAMZA RAMUCIRUMAB ELI LILLY NEDERLAND BV DACOGEN DECITABINE JANSSEN-CILAG INTERNATIONAL NV DAKLINZA DACLATASVIR BRISTOL MYERS SQUIBB/PFIZER EEIG DALIRESP ROFLUMILAST 500.00 MCG NYCOMED GMBH DAPHNE ETHINYLESTRADIOL 35.00 MCG, CYPROTERONE ACETATE 2.00 MG MITHRA PHARMACEUTICALS S.A. DAXAS ROFLUMILAST NYCOMED GMBH DEFITELIO DEFIBROTIDE Gentium New biological, authorised under exceptional circumstances DELTYBA DELAMANID Otsuka Novel Products GmbH, Cond Auth DEPAKINE SODIUM VALPROATE SANOFI BELGIUM DEPAKINE CHRONO SODIUM VALPROATE, VALPROIC ACID SANOFI BELGIUM DEPAKINE CHRONO SODIUM VALPROATE, VALPROIC ACID PI-PHARMA NV DEPAKINE ENTERIC SODIUM VALPROATE SANOFI BELGIUM DEPAKINE IV SODIUM VALPROATE SANOFI BELGIUM DIANE-35 ETHINYLESTRADIOL 35.00 MCG, CYPROTERONE ACETATE 2.00 MG BAYER N.V. DIFICLIR FIDAXOMICIN ASTELLAS PHARMA EUROPE B.V. DOMPERIDON MYLAN DOMPERIDONE MALEATE MYLAN SPRL DOMPERIDON TEVA DOMPERIDONE MALEATE TEVA PHARMA BELGIUM N.V. DOMPERIDONE EG DOMPERIDONE MALEATE EUROGENERICS N.V. DOMPERIDONE INSTANT DOMPERIDONE EG EUROGENERICS N.V. DOMPERIDONE MYLAN DOMPERIDONE MALEATE MYLAN BVBA/SPRL DOMPERITOP DOMPERIDONE MALEATE APOTEX NV DUAKLIR GENUAIR ACLIDINIUM BROMIDE/ FORMOTERL FUMARATE DIHYDRATE ALMIRALL S.A EDARBI AZILSARTAN MEDOXOMIL (POTASSIUM) TAKEDA GLOBAL R&D CENTRE (EUROPE) LTD EDURANT RILPIVIRINE (HYDROCHLORIDE) JANSSEN-CILAG INTERNATIONAL NV EKISTOL CILOSTAZOL??? Outcome Referral Art 31, EKLIRA GENUAIR ACLIDINIUM (BROMURE) ALMIRALL S.A., ELAPRASE IDURSULFASE SHIRE HUMAN GENETIC THERAPIES AB Auth under excep circumstances ELIQUIS APIXABAN BRISTOL MYERS SQUIBB/PFIZER EEIG ELISAMYLAN 35 ETHINYLESTRADIOL 35.00 MCG, CYPROTERONE ACETATE 2.00 MG MYLAN BVBA/SPRL ELVANSE / TYVENSE LISDEXAMPHETAMINE BRYSTOL MYERS SQUIBB/ PFIZER EEIG ENTYVIO VEDOLIZUMAB TAKEDA PHARMA A/S

ENUREV BREEZHALER GLYCOPYRRONIUM (BROMIDE) NOVARTIS EUROPHARM LIMITED, EPERZAN ALBIGLUTIDE GlaxoSmithKline Trading Services Limited ERIVEDGE VISMODEGIB ROCHE REGISTRATION LIMITED, Cond Auth ESBRIET PIRFENIDONE INTERMUNE EUROPE LTD, EURARTESIM PIPERAQUINE TETRAPHOSPHATE (TETRAHYDRATE), DIHYDROARTEMISININ (DHA) SIGMA-TAU INDUSTRIE FARMAC. RIUNITE SPA, EVARREST FIBRINOGEN, HUMAN Q.S., THROMBIN, HUMAN Q.S. OMRIX BIOPHARMACEUTICALS N.V. New Biological EVIPLERA ENOFOVIR DISOPROXIL (FUMARATE), EMTRICITABINE GILEAD SCIENCES LTD, RILPIVIRINE (HYDROCHLORIDE) EVOLTRA CLOFARABINE GENZYME EUROPE B.V. Auth under excep circumstances EXJADE DEFERASIROX NOVARTIS EUROPHARM LIMITED EXVIERA DASABUVIR ABBVIE LTD EYLEA AFLIBERCEPT BAYER AG EZICLEN SULPHATE ANHYDROUS, MAGNESIUM SULFATE HEPTAHYDRATE, POTASSIUM SULPHATE IPSEN PHARMA FAMPYRA FAMPRIDINE BIOGEN IDEC LTD, Cond Auth FIRDAPSE AMIFAMPRIDINE (PHOSPHATE) BIOMARIN EUROPE LTD Auth under excep circumstances, FLUENZ INFLUENZA VIRUS, LIVE, ATTENUATED Q.S. MEDIMMUNE LLC FLUENZ TETRA INFLUENZA VIRUS (LIVE, ATTENUATED Q.S., NASAL) MEDIMMUNE LLC FORXIGA DAPAGLIFLOZIN (PROPANEDIOL MONOHYDRATE) BRISTOL MYERS SQUIBB/ASTRAZENECA EEIG FYCOMPA PERAMPANEL EISAI EUROPE LTD GAZYVARO OBINUTUZUMAB ROCHE REGISTRATION LIMITED GEONISTIN OXYTETRACYCLIN, NYSTATIN Pliva Hrvatska d.o.o. GILENYA FINGOLIMOD (HYDROCHLORIDE) 0.50 MG NOVARTIS EUROPHARM LIMITED, GIOTRIF AFATINIB Boehringer Ingelheim International GLIVEC IMATINIB NOVARTIS EUROPHARM LIMITED GLYBERA ALIPOGENE TIPARVOVEC Q.S. UNIQURE BIOPHARMA B.V, Auth under excep circumstances, GRASTOFIL FILGASTRIM Apotex Europe New Biological GRATIELLA 35 ETHINYLESTRADIOL 35.00 MCG, CYPROTERONE ACETATE 2.00 MG 3DDD PHARMA N.V. HAES-STERIL 6% HYDROXYETHYL STARCH FRESENIUS KABI NV Outcome Referral Art 31, HAES-STERIL 10% HYDROXYETHYL STARCH FRESENIUS KABI NV Outcome Referral Art 31, HALAVEN ERIBULIN (MESYLATE) 0.44 MG/ML EISAI LIMITED HARVONI LEDIPASVIR, SOFOSBUVIR GILEAD SCIENCES LTD HELEN CHLORMADINONE, ETHINYLESTRADIOL Mithra Pharmaceuticals S.A. Outcome Referral Art 31,

HEXACIMA HEXYON Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rdna), poliomyelitis (inactivated) and Haemophilus influenzae type B conjugate vaccine (adsorbed) Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rdna), poliomyelitis (inactivated) and Haemophilus influenzae type B conjugate vaccine (adsorbed) SANOFI PASTEUR SA SANOFI PASTEUR MSD New Biological New Biological HIZENTRA IMMUNOGLOBULIN HUMAN NORMAL 200.00 MG/ML BIOCLS GMBH New Biological HOLOCLAR EX VIVO EXPENDED AUTOLOGOUS HUMAN CORNEAL EPITHELIAL CELLS CONTAINING STEM CELLS CHIESI FARMACEUTICI SPA, Cond Auth HYQVIA IMMUNOGLOBULIN HUMAN NORMAL 100.00 MG/ML BAXTER INNOVATIONS GMBH New Biological ICLUSIG PONATINIB (HYDROCHLORIDE) ARIAD PHARMA LTD ILARIS CANAKINUMAB NOVARTIS EUROPHARM LIMITED Auth under excep circumstances, IMBRUVICA IBRUTINIB JANSSEN-CILAG INTERNATIONAL NV IMNOVID (POMALIDOMIDE POMALIDOMIDE CELGENE EUROPE LIMITED, CELGENE) IMVANEX Modified Vaccinia Ankara virus - Bavarian Nordic, Auth under excep BAVARIAN NORDIC A/S (MVA-BN) live virus circumstances INCIVO TELAPREVIR JANSSEN-CILAG INTERNATIONAL NV INCRELEX MECASERMIN IPSEN PHARMA Auth under excep circumstances, INCRESYNC ALOGLIPTIN/PIOGLITAZONE TAKEDA PHARMA A/S INCRUSE UMECLIDINIUM BROMIDE Glaxo Group Ltd INFLECTRA NFLIXIMAB HOSPIRA UK LTD New Biological INFLUSPLIT/ FLUARIX TETRA Influenza virus inactivated split virion GLAXO GROUP LTD Biological INLYTA AXITINIB PFIZER LIMITED INVOKANA CANAGLIFLOZIN JANSSEN-CILAG INTERNATIONAL NV IPREZIV AZILSARTAN MEDOXOMIL (POTASSIUM) TAKEDA GLOBAL R&D CENTRE (EUROPE) LTD JAKAVI RUXOLITINIB (PHOSPHATE) NOVARTIS EUROPHARM LIMITED, JARDIANCE EMPAGLIFLOZIN BOEHRINGER INGELHEIM INTERNATIONAL GMBH JAYDESS LEVONORGESTREL 13.50 MG BAYER N.V. JENTADUETO METFORMIN HYDROCHLORIDE, LINAGLIPTIN BOEHRINGER INGELHEIM INTERNATIONAL GMBH

JETREA OCRIPLASMIN THROMBOGENICS NV JEVTANA CABAZITAXEL SANOFI-AVENTIS GROUPE KADCYLA TRASTUZUMAB EMTANSINE ROCHE REGISTRATION LIMITED KALYDECO IVACAFTOR VERTEX PHARMACEUTICALS LIMIT, KETOCONAZOLE HRA KETOCONAZOLE LABORATOIRE HRA PHARMA KOLBAM (previously CHOLIC ACID FGK) CHOLIC ACID FGK Representative Service GmbH Auth under excep circumstances KRYSTEXXA PEGLOTICASE SAVIENT PHARMA IRELAND LIMITED, LACTEST GASILOXE Lactest S.L. / Venter Pharma S.L. LATUDA LURASIDONE TAKEDA PHARMA A/S LAVENTAIR UMECLIDINIUM BROMIDE, VILANTEROL TRIFENATATE GLAXO GROUP LTD, LEMTRADA ALEMTUZUMAB GENZYME THERAPEUTICS LTD New Biological LIBERTEK ROFLUMILAST NYCOMED GMBH LOJUXTA LOMITAPIDE (MESYLATE) AEGERION PHARMACEUTICALS, Auth under excep circumstances LONQUEX LIPEGFILGRASTIM TEVA PHARMA BV, LYMPHOSEEK TILMANOCEPT NAVIDEA BIOPHARMACEUTICALS LIMITED LTD LYNPARZA OLAPARIB ASTRAZENECA AB LYXUMIA LIXISENATIDE SANOFI-AVENTIS GROUPE MACI CHONDROCYTES, AUTOLOGOUS CULTURED Q.S. GENZYME EUROPE B.V. MEKINIST TRAMETINIB GLAXO GROUP LTD MERIOFERT MENOTROPHIN LABORATOIRE GENEVRIER SA New Biological MOTILIUM DOMPERIDONE MALEATE JOHNSON & JOHNSON CONSUMER N.V. MOTILIUM DOMPERIDONE JOHNSON & JOHNSON CONSUMER N.V. MOTILIUM DOMPERIDONE PI-PHARMA NV MOTILIUM DOMPERIDONE IMPEXECO SA MOVENTIG NALOXEGOL ASTRAZENECA AG NAGLAZYME GALSULFASE BIOMARIN EUROPE LTD Auth under excep circumstances, NEURACEQ FLORBETABEN (18F) Piramal Imaging GmbH NEXOBRID PROTEOLYTIC ENZYMES (CONCENTRATE) ENRICHED IN MEDIWOUND GERMANY BROMELAIN, NIMENRIX NEISSERIA MENINGITIDES A+C+W+Y, POLYSACCHARIDE CONJ. TO TETANUS TOXOID Q.S. GLAXOSMITHKLINE BIOLOGICALS S.A., NOVOEIGHT Turoctocog alfa NOVO NORDISK A/S NOVOTHIRTEEN CATRIDECACOG NOVO NORDISK A/S NULOJIX BELATACEPT BRISTOL-MYERS SQUIBB PHARMA EEIG

NUMETZAH G16%E alanine, arginine, aspartic acid, calcium chloride, cysteine, glucose monohydrate, glutamic acid, glycine, histidine, isoleucine, leucine, lysine monohydrate, magnesium acetate, methionine, olive oil, ornithine hydrochloride, henylalanine, potassium acetate, BAXTER S.A. Outcome Referral Art 31, proline, serine, sodium chloride, sodium glycerophosphate, soybean oil, taurine, threonine, tryptophan, tyrosine, valine NUWIQ SIMOCTOCOG ALFA OCTAPHARMA AB OFEV NINTEDANIB BOEHRINGER INGELHEIM INTERNATIONAL GMBH OLYSIO SIMEPREVIR JANSSEN-CILAG INTERNATIONAL NV OPGENRA EPTOTERMIN ALFA OLYMPUS BIOTECH LTD OPSUMIT MACITENTAN Actelion Registration Ltd OPTIMARK GADOVERSETAMIDE MALLINCKRODT MEDICAL GMBH OROPERIDYS DOMPERIDONE PIERRE FABRE MEDICAMENT ORPHACOL CHOLIC ACID LABORATOIRES CTRS Auth under excep circumstances OSSEOR STRONTIUM RANELATE SERVIER, LES LABORATOIRES OTEZLA APREMILAST CELGENE EUROPE LIMITED OVALEAP FOLLITROPIN ALPHA TEVA PHARMA GMBH New Biological PANDEMRIX INFLUENZA VIRUS (INACTIVATED) Q.S. GLAXOSMITHKLINE BIOLOGICALS S.A. PERJETA PERTUZUMAB ROCHE REGISTRATION LIMITED PICATO INGENOL MEBUTATE LEO PHARMA A/S PIXUVRI PIXANTRONE (DIMALEATE) CTI LIFE SCIENCES LTD, Cond Auth PLASMAVOLUME REDIBAG 6% HYDROXYETHYL STARCH BAXTER S.A. Outcome Referral Art 31, PLEGRIDY PEGINTERFERON BETA-1A BIOGEN IDEC LTD PLETAL CILOSTAZOL??? Outcome Referral Art 31, PROCORALAN IVABRADINE SERVIER, LES LABORATOIRES PROTELOS STRONTIUM RANELATE SERVIER, LES LABORATOIRES PROVENGE AUTOLOGOUS PERIPHERAL BLOOD MONONUCLEAR CELLS ACTIVATED WITH PAP-GM-CS Q.S. DENDREON UK LIMITED, RELVAR ELLIPTA FLUTICASONE FUROATE: VILANTEROL TRIFENATATE GLAXO GROUP LTD, REMSIMA INFLIXIMAB CELLTRION HEALTHCARE HUNGARY KFT. New Biological REPLAGAL AGALSIDASE ALFA SHIRE HUMAN GENETIC THERAPIES AB Auth under excep circumstances, REVESTIVE TEDUGLUTIDE NYCOMED DANMARK APS,

REVLIMID LENALIDOMIDE CELGENE EUROPE LIMITED REVINTY ELLIPTA FLUTICASONE FUROATE: VILANTEROL TRIFENATATE GLAXO GROUP LTD RIENSO FERUMOXYTOL TAKEDA PHARMA A/S RIXUBIS NONACOG GAMMA BAXTER INNOVATIONS GMBH New Biological RYZODEG INSULIN ASPART 30.00 UML, INSULIN DEGLUDEC 70.00 UML NOVO NORDISK A/S SCENESSE AFAMELANOTIDE CLINUVEL UK LIMITED, Auth under excep circumstances SEEBRI BREEZHALER GLYCOPYRRONIUM (BROMIDE) NOVARTIS EUROPHARM LIMITED, SELINCRO NALMEFENE (HYDROCHLORIDE DIHYDRATE) LUNDBECK A/S SENCHIO OSPEMIFENE SHIONOGI LIMITED New as, SIGNIFOR PASIREOTIDE (DIASPARTATE) NOVARTIS EUROPHARM LIMITED SIRTURO BEDAQUILINE JANSSEN-CILAG INTERNATIONAL NV, conditional auth SOMATROPIN BIOPARTNERS SOMATROPIN BIOPARTNERS New Biological SOVALDI SOFOSBUVIR GILEAD SCIENCES INTERNATIONAL LTD SPEDRA AVANAFIL VIVUS BV STIVARGA REGORAFENIB BAYER AG STRIBILD TENOFOVIR DISOPROXIL (FUMARATE), EMTRICITABINE, ELVITEGRAVIR, COBICISTAT GILEAD SCIENCES LTD STRIVERDI RESPIMAT OLODATEROL BOEHRINGER INGELHEIM INTERNATIONAL GMBH, SYLVANT SILTUXIMAB JANSSEN-CILAG INTERNATIONAL NV TAFINLAR DABRAFENIB GLAXOSMITHKLINE TRADING SERVICES LIMITED TARGOCID ACIPIMOX PFIZER TETRASPAN 6% HYDROXYETHYL STARCH B. BRAUN MELSUNGEN AG Outcome Referral Art 31, TETRASPAN 10% HYDROXYETHYL STARCH B. BRAUN MELSUNGEN AG Outcome Referral Art 31, TEYSUNO TEGAFUR, GIMERACIL, OTERACIL (MONOPOTASSIUM) NORDIC GROUP BV, TIVICAY DOLUTEGRAVIR ViiV Healthcare UK Limited TOVANOR BREEZHALER GLYCOPYRRONIUM (BROMIDE) NOVARTIS EUROPHARM LIMITED, TRAJENTA LINAGLIPTIN BOEHRINGER INGELHEIM INTERNATIONAL GMBH TRANSLARNA ATALUREN PTC Therapeutics Limited, conditional auth TRESIBA INSULIN DEGLUDEC NOVO NORDISK A/S TRIUMEQ DOLUTEGRAVIR, ABACAVIR, LAMIVUDINE VIIV HEALTHCARE UK Ltd TROBALT RETIGABINE GLAXO GROUP LTD TYBOST COBICISTAT Gilead Sciences

TYGACIL TIGECYCLINE PFIZER LIMITED TYSABRI NATALIZUMAB BIOGEN IDEC LTD TYVERB LAPATINIB (DITOSYLATE MONOHYDRATE) GLAXO GROUP LTD Conditional auth ULTIBRO BREEZHALER INDACATEROL (MALEATE), GLYCOPYRRONIUM (BROMIDE) NOVARTIS EUROPHARM LIMITED ULUNAR BREEZHALER INDACATEROL (MALEATE), GLYCOPYRRONIUM (BROMIDE) NOVARTIS EUROPHARM LIMITED VALPROATE MYLAN SODIUM VALPROATE MYLAN BVBA VALPROATE RETARD EG SODIUM VALPROATE, VALPROIC ACID EG VALPROATE RETARD MYLAN SODIUM VALPROATE MYLAN BVBA VALPROATE SANDOZ SODIUM VALPROATE, VALPROIC ACID SANDOZ NV VECTIBIX PANITUMUMAB 20.00 MG/ML AMGEN EUROPE BV Conditional auth VEDROP TOCOPHEROL D-ALPHA (AS TOCOFERSOLAN) ORPHAN EUROPE SARL Auth under excep circumstances, VELPHORO Mixture of polynuclear iron(iii)-oxyhydroxide, sucrose Vifor Fresenius Medical Care Renal Pharma France and starches VENOHES 6% HYDROXYETHYL STARCH B. BRAUN MELSUNGEN AG Outcome Referral Art 31, VEPACEL INFLUENZA VIRUS (INACTIVATED) Q.S. BAXTER INNOVATIONS GMBH VIBATIV TELAVANCIN Clinigen Healthcare Limited VICTRELIS BOCEPREVIR MERCK SHARP & DOHME LTD VIEKIRAX OMBITASVIR, PARITAPREVIR, RITONAVIR ABBVIE LTD VIMIZIM ELOSULFASE ALFA BIOMARIN EUROPE LTD, VIPDOMET ALOGLYPTIN / METFORMIN TAKEDA PHARMA A/S VIPIDIA ALOGLYPTIN TAKEDA PHARMA A/S VITEKTA ELVITEGRAVIR Gilead Sciences International Ltd VIZAMYL FLUTEMETAMOL (18F) GE Healthcare Ltd VOKANAMET CANAGLIFLOZIN / METFORMIN HYDROCHLORIDE JANSSEN-CILAG INTERNATIONAL NV VOLULYTE 6% HYDROXYETHYL STARCH FRESENIUS KABI NV Outcome Referral Art 31, VOLUVEN 6% HYDROXYETHYL STARCH FRESENIUS KABI NV Outcome Referral Art 31, VOLUVEN 10% HYDROXYETHYL STARCH FRESENIUS KABI NV Outcome Referral Art 31, VONCENTO FACTOR VIII HUMAN 1000.00 IU, FACTOR VON WILLEBRAND 2400.00 IU TEVA PHARMA BV New Biological VOTUBIA EVEROLIMUS NOVARTIS EUROPHARM LIMITED Conditional auth VYNDAQEL TAFAMIDIS (MEGLUMINE) PFIZER LIMITED Auth under excep circumstances, New AS, XADAGO SAFINAMIDE ZAMBON SPA XAGRID XAGRID SHIRE PHARMACEUTICAL CONTRACTS LTD Auth under excep circumstances XALKORI CRIZOTINIB PFIZER LIMITED, Cond Auth XARELTO RIVAROXABAN 10.00 MG BAYER SCHERING PHARMA AG

XGEVA DENOSUMAB AMGEN EUROPE BV New biological XIAPEX COLLAGENASE CLOSTRIDIUM HISTOLYTICUM AUXILIUM UK LIMITED XIGDUO DAPAGLIFLOZIN/METFORMIN BRISTOL MYERS SQUIBB/PFIZER EEIG XOFIGO Radium Ra 223 dichloride Bayer Pharma AG XOTERNA BREEZHALER INDACATEROL / GLYCOPYRRONIUM TEVA PHARMA BV XTANDI ENZALUTAMIDE ASTELLAS PHARMA EUROPE B.V. XULTOPHY INSULIN DEGLUDEC, LIRAGLUTIDE NOVO NORDISK A/S New Biological XYDALBA DALBAVANCIN DURATA THERAPEUTICS INTERNATIONAL bv YELLOX BROMFENAC (SODIUM SESQUIHYDRATE) CROMA-PHARMA GMBH YERVOY IPILIMUMAB BRISTOL-MYERS SQUIBB PHARMA EEIG, YONDELIS TRABECTEDIN PHARMA MAR SA Auth under excep circumstances ZALTRAP AFLIBERCEPT SANOFI-AVENTIS GROUPE ZELBORAF VEMURAFENIB ROCHE REGISTRATION LIMITED ZILIUM DOMPERIDONE MALEATE KELA PHARMA NV ZINFORO CEFTAROLINE FOSAMIL (ACETIC ACID SOLVATE MONOHYDRATE) ASTRAZENECA AB ZOELY THERAMEX S.r.l. NOMOGESTROL ACETATE / ESTRADIOL HEMIHYDRATE ZONTIVITY VORAPAXAR MERCK SHARP & DOHME LTD ZYDELIG IDELALISIB GILEAD SCIENCES INTERNATIONAL LTD ZYTIGA ABIRATERONE ACETATE JANSSEN-CILAG INTERNATIONAL NV NOTE In Red in Black in blue in grey New Biological commercialised / commercialisé / gecommercialiseerd not commercialised / pas commercialisé / niet gecommercialiseerd info not yet available / info non disponible / info niet beschikbaar New addition of this month / nouvelle addition de ce mois / nieuwe toevoeging van deze maand nouvelle substance active / nieuw actief bestanddeel nouveau médicament biologique / nieuwe biologische geneesmiddel Etude de sécurité post-autorisation / post-autorisatie veiligheidsstudies

Conditional auth Auth under excep circumstances Autorisé sous certaines conditions / vergund onder bepaalde voorwaarden autorisé sous circonstances exceptionnelles / vergund onder uitzonderlijke omstandigheden Product informations / informations sur les produits / produkten informaties informations sur les produits/productinformatie http://www.fagg-afmps.be/search?language=fr&search_field=notice